Encyclopedia of Signaling Molecules

Living Edition
| Editors: Sangdun Choi

TPL2

  • Dimitra Virla
  • Christos Tsatsanis
  • Aristides G. Eliopoulos
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-6438-9_626-1

Synonyms

Historical Background

The Tpl2 gene, also known as COT and MAP3K8 (Vougioukalaki et al. 2011), was independently discovered by three research teams in the early 1990s. COT (Cancer Osaka thyroid) was initially described by Miyoshi et al. as a putative human proto-oncogene, isolated from a human thyroid carcinoma cell line and discovered to have a rearranged 3′ end in the last coding exon (Miyoshi et al. 1991). The rat homologue of COT, named tumor progression locus ( Tpl2), was identified by Tsichlis et al. as a proto-oncogene that is activated by provirus integration in Moloney murine leukemia virus (MoMuLV)-induced T-cell lymphomas and capable to transform NIH 3T3 fibroblasts in vitro (Patriotis et al. 1993). In mice, the Tpl2gene locus is also targeted by provirus insertion in mouse mammary tumor virus (MMTV)-associated mammary carcinomas in mice...

Keywords

iNKT Cell Tumor Progression Locus Provirus Insertion Alternative Translation Initiation Site Human Thyroid Carcinoma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

Dimitra Vyrla was supported through the action “Funding of Postdoctoral Researchers” of the Operational Program “Development of Human Resources, Education and Lifelong Learning,” 2014–2020, implemented by State Schlolarships Foundation (IKY) and cofinanced by the European Social Fund and the Greek State.

References

  1. Aoki M, Hamada F, Sugimoto T, Sumida S, Akiyama T, Toyoshima K. The human cot proto-oncogene encodes two protein serine/threonine kinases with different transforming activities by alternative initiation of translation. J Biol Chem. 1993;268:22723–32.PubMedGoogle Scholar
  2. Banerjee A, Grumont R, Gugasyan R, White C, Strasser A, Gerondakis S. NF-kappaB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms. Blood. 2008;112:5063–73.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Beinke S, Deka J, Lang V, Belich MP, Walker PA, Howell S, Smerdon SJ, Gamblin SJ, Ley SC. NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol. 2003;23:4739–52.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Belich MP, Salmeron A, Johnston LH, Ley SC. Tpl-2 kinase regulates the proteolysis of the NF-kB-inhibitory protein NF-kB1 p105. Nature. 1999;397:363–8.CrossRefPubMedGoogle Scholar
  5. Ben-Addi A, Mambole-Dema A, Brender C, Martin SR, Janzen J, Kjaer S, Smerdon SJ, Ley SC. IkappaB kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases. Proc Natl Acad Sci U S A. 2014;111:E2394–403.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Ceci JD, Patriotis CP, Tsatsanis C, Makris AM, Kovatch R, Swing DA, Jenkins NA, Tsichlis PN, Copeland NG. Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev. 1997;11:688–700.CrossRefPubMedGoogle Scholar
  7. Chiariello M, Marinissen MJ, Gutkind JS. Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol Cell Biol. 2000;20:1747–58.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Cho J, Melnick M, Solidakis GP, Tsichlis PN. Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals. J Biol Chem. 2005;280:20442–8.CrossRefPubMedGoogle Scholar
  9. Choi HS, Kang BS, Shim JH, Cho YY, Choi BY, Bode AM, Dong Z. Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of c-fos transcriptional activity. FASEB J. 2008;22:113–26.CrossRefPubMedGoogle Scholar
  10. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, Tsatsanis C. Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol Cancer. 2004;3:34.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K, Tsichlis PN. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem. 2005;280:23748–57.CrossRefPubMedGoogle Scholar
  12. Decicco-Skinner KL, Trovato EL, Simmons JK, Lepage PK, Wiest JS. Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis. Oncogene. 2011;30:389–97.CrossRefPubMedGoogle Scholar
  13. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G, Tsichlis PN. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103:1071–83.CrossRefPubMedGoogle Scholar
  14. Eliopoulos AG, Davies C, Blake SS, Murray P, Najafipour S, Tsichlis PN, Young LS. The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2. J Virol. 2002a;76:4567–79.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Eliopoulos AG, Dumitru CD, Wang C-C, Cho J, Tsichlis PN. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002b;21:4831–40.CrossRefPubMedGoogle Scholar
  16. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 2003;22:3855–64.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Erny KM, Peli J, Lambert JF, Muller V, Diggelmann H. Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. Oncogene. 1996;13:2015–20.PubMedGoogle Scholar
  18. Gandara ML, Lopez P, Hernando R, Castano JG, Alemany S. The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity. Mol Cell Biol. 2003;23:7377–90.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Gkirtzimanaki K, Gkouskou KK, Oleksiewicz U, Nikolaidis G, Vyrla D, Liontos M, Pelekanou V, Kanellis DC, Evangelou K, Stathopoulos EN, Field JK, Tsichlis PN, Gorgoulis V, Liloglou T, Eliopoulos AG. TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A. 2013;110:E1470–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Gomez-Casero E, San-Antonio B, Iniguez MA, Fresno M. Cot/Tpl2 and PKCzeta cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain. Cell Signal. 2007;19:1652–61.CrossRefPubMedGoogle Scholar
  21. Gruosso T, Garnier C, Abelanet S, Kieffer Y, Lemesre V, Bellanger D, Bieche I, Marangoni E, Sastre-Garau X, Mieulet V, Mechta-Grigoriou F. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun. 2015;6:8583.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Guo J, Zhang J, Zhang X, Zhang Z, Wei X, Zhou X. Constitutive activation of MEK1 promotes Treg cell instability in vivo. J Biol Chem. 2014;289:35139–48.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Gutmann S, Hinniger A, Fendrich G, Druckes P, Antz S, Mattes H, Mobitz H, Ofner S, Schmiedeberg N, Stojanovic A, Rieffel S, Strauss A, Troxler T, Glatthar R, Sparrer H. The crystal structure of Cancer Osaka thyroid kinase reveals an unexpected kinase domain fold. J Biol Chem. 2015;290:15210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Hall JP, Kurdi Y, Hsu S, Cuozzo J, Liu J, Telliez JB, Seidl KJ, Winkler A, Hu Y, Green N, Askew GR, Tam S, Clark JD, Lin LL. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007;282:33295–304.CrossRefPubMedGoogle Scholar
  25. Hatziapostolou M, Koukos G, Polytarchou C, Kottakis F, Serebrennikova O, Kuliopulos A, Tsichlis PN. Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal. 2011;4:ra55.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Hatziapostolou M, Polytarchou C, Panutsopulos D, Covic L, Tsichlis PN. Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. Cancer Res. 2008;68:1851–61.CrossRefPubMedGoogle Scholar
  27. Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014;123:3305–15.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Jager J, Gremeaux T, Gonzalez T, Bonnafous S, Debard C, Laville M, Vidal H, Tran A, Gual P, Le Marchand-Brustel Y, Cormont M, Tanti JF. Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes. 2009;59:61–70.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Jeong JH, Bhatia A, Toth Z, Oh S, Inn KS, Liao CP, Roy-Burman P, Melamed J, Coetzee GA, Jung JU. TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One. 2011;6:e16205.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968–72.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, Yang HT, Grant S, Ricciardi-Castagnoli P, Tsichlis PN, Ley SC, O’Garra A. TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J Exp Med. 2009;206:1863–71.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Kakimoto K, Musikacharoen T, Chiba N, Bandow K, Ohnishi T, Matsuguchi T. Cot/Tpl2 regulates IL-23 p19 expression in LPS-stimulated macrophages through ERK activation. J Physiol Biochem. 2010;66:47–53.CrossRefPubMedGoogle Scholar
  33. Kanellis DC, Bursac S, Tsichlis PN, Volarevic S, Eliopoulos AG. Physical and functional interaction of the TPL2 kinase with nucleophosmin. Oncogene. 2015;34:2516–26.CrossRefPubMedGoogle Scholar
  34. Kaniaris E, Vaporidi K, Vergadi E, Theodorakis EE, Kondili E, Lagoudaki E, Tsatsanis C, Georgopoulos D. Genetic and pharmacologic inhibition of Tpl2 kinase is protective in a mouse model of ventilator-induced lung injury. Intensive Care Med Exp. 2014;2:15.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Kannan Y, Perez-Lloret J, Li Y, Entwistle LJ, Khoury H, Papoutsopoulou S, Mahmood R, Mansour NR, Ching-Cheng Huang S, Pearce EJ, Pedro SCL, Ley SC, Wilson MS. TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology. PLoS Pathog. 2016;12:e1005783.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Khanal P, Lee KY, Kang KW, Kang BS, Choi HS. Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF. Carcinogenesis. 2009;30:682–9.CrossRefPubMedGoogle Scholar
  37. Kim JY, Lim SC, Kim G, Yun HJ, Ahn SG, Choi HS. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene. 2015;34:4928–38.CrossRefPubMedGoogle Scholar
  38. Koliaraki V, Roulis M, Kollias G. Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest. 2012;122:4231–42.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, Kotlyarov A, Forster I, Flavell R, Gaestel M, Tsichlis P, Cominelli F, Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn’s-like inflammatory bowel disease. J Exp Med. 2002;196:1563–74.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Kyrmizi I, Ioannou M, Hatziapostolou M, Tsichlis PN, Boumpas DT, Tassiulas I. Tpl2 kinase regulates FcgammaR signaling and immune thrombocytopenia in mice. J Leukoc Biol. 2013;94:751–7.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Lee HW, Cho HJ, Lee SJ, Song HJ, Cho HJ, Park MC, Seol HJ, Lee JI, Kim S, Lee HM, Choi HY, Nam DH, Joo KM. Tpl2 induces castration resistant prostate cancer progression and metastasis. Int J Cancer. 2015;136:2065–77.CrossRefPubMedGoogle Scholar
  42. Lin X, Cunningham ET, Mu Y, Geleziunas R, Greene WC. The proto-oncogene Cot kinase participates in CD3/CD28 induction of NF-kB acting through the NF-kB-inducing kinase and IkB kinases. Immunity. 1999;10:271–80.CrossRefPubMedGoogle Scholar
  43. Mielke LA, Elkins KL, Wei L, Starr R, Tsichlis PN, O’Shea JJ, Watford WT. Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol. 2009;183:7984–93.CrossRefPubMedPubMedCentralGoogle Scholar
  44. Miyoshi J, Higashi T, Mukai H, Ohuchi T, Kakunaga T. Structure and transforming potential of the human Cot oncogene encoding a putative protein kinase. Mol Cell Biol. 1991;11:4088–96.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Ohara R, Hirota S, Onoue H, Nomura S, Kitamura Y, Toyoshima K. Identification of the cells expressing cot proto-oncogene mRNA. J Cell Sci. 1995;108(Pt 1):97–103.PubMedGoogle Scholar
  46. Ohnishi T, Okamoto A, Kakimoto K, Bandow K, Chiba N, Matsuguchi T. Involvement of Cot/Tp12 in bone loss during periodontitis. J Dent Res. 2010;89:192–7.CrossRefPubMedGoogle Scholar
  47. Papoutsopoulou S, Symons A, Tharmalingham T, Belich MP, Kaiser F, Kioussis D, O’Garra A, Tybulewicz V, Ley SC. ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses. Nat Immunol. 2006;7:606–15.CrossRefPubMedGoogle Scholar
  48. Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A. 1993;90:2251–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Perugorria MJ, Murphy LB, Fullard N, Chakraborty JB, Vyrla D, Wilson CL, Oakley F, Mann J, Mann DA. Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice. Hepatology. 2013;57:1238–49.CrossRefPubMedGoogle Scholar
  50. Robinson MJ, Beinke S, Kouroumalis A, Tsichlis PN, Ley SC. Phosphorylation of TPL-2 on serine 400 is essential for lipopolysaccharide activation of extracellular signal-regulated kinase in macrophages. Mol Cell Biol. 2007;27:7355–64.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Roulis M, Nikolaou C, Kotsaki E, Kaffe E, Karagianni N, Koliaraki V, Salpea K, Ragoussis J, Aidinis V, Martini E, Becker C, Herschman HR, Vetrano S, Danese S, Kollias G. Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. Proc Natl Acad Sci U S A. 2014;111:E4658–67.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Rousseau S, Papoutsopoulou M, Symons A, Cook D, Lucocq JM, Prescott AR, O’Garra A, Ley SC, Cohen P. TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNF alpha in LPS-stimulated macrophages. J Cell Sci. 2008;121:149–54.CrossRefPubMedGoogle Scholar
  53. Salmeron A, Ahmad TB, Carlile GW, Pappin D, Narsimhan RP, Ley SC. Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase. EMBO J. 1996;15:817–26.PubMedPubMedCentralGoogle Scholar
  54. Serebrennikova OB, Tsatsanis C, Mao C, Gounaris E, Ren W, Siracusa LD, Eliopoulos AG, Khazaie K, Tsichlis PN. Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc Natl Acad Sci U S A. 2012;109:E1082–91.CrossRefPubMedPubMedCentralGoogle Scholar
  55. Sriskantharajah S, Guckel E, Tsakiri N, Kierdorf K, Brender C, Ben-Addi A, Veldhoen M, Tsichlis PN, Stockinger B, O’Garra A, Prinz M, Kollias G, Ley SC. Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase. J Immunol. 2014;192:3518–29.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Stafford MJ, Morrice NA, Peggie MW, Cohen P. Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett. 2006;580:4010–4.CrossRefPubMedGoogle Scholar
  57. Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, Masuda A, Yoshikai Y, Takamoto M, Sugane K, Matsuo S, Shimada Y, Matsuguchi T. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. J Clin Invest. 2004;114:857–66.CrossRefPubMedPubMedCentralGoogle Scholar
  58. Tsatsanis C, Patriotis C, Bear SE, Tsichlis PN. The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and induces interleukin 2 expression in T cells. Proc Natl Acad Sci U S A. 1998a;95:3827–32.CrossRefPubMedPubMedCentralGoogle Scholar
  59. Tsatsanis C, Patriotis C, Tsichlis PN. Tpl-2 induces IL-2 expression in T cell lines by triggering multiple signaling pathways that activate NFAT and NF-kB. Oncogene. 1998b;17:2609–18.CrossRefPubMedGoogle Scholar
  60. Tsatsanis C, Vaporidi K, Zacharioudaki V, Androulidaki A, Sykulev Y, Margioris AN, Tsichlis PN. Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells. Proc Natl Acad Sci U S A. 2008;105:2987–92.CrossRefPubMedPubMedCentralGoogle Scholar
  61. Varin EM, Wojtusciszyn A, Broca C, Muller D, Ravier MA, Ceppo F, Renard E, Tanti JF, Dalle S. Inhibition of the MAP3 kinase Tpl2 protects rodent and human beta-cells from apoptosis and dysfunction induced by cytokines and enhances anti-inflammatory actions of exendin-4. Cell Death Dis. 2016;7:e2065.CrossRefPubMedPubMedCentralGoogle Scholar
  62. Vougioukalaki M, Kanellis DC, Gkouskou K, Eliopoulos AG. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 2011;304:80–9.CrossRefPubMedGoogle Scholar
  63. Vyrla D, Nikolaidis G, Oakley F, Perugorria MJ, Tsichlis PN, Mann DA, Eliopoulos AG. TPL2 kinase is a crucial signaling factor and mediator of NKT effector cytokine expression in immune-mediated liver injury. J Immunol. 2016;196:4298–310.CrossRefPubMedGoogle Scholar
  64. Waterfield MR, Zhang M, Norman LP, Sun SC. NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. Mol Cell. 2003;11:685–94.CrossRefPubMedGoogle Scholar
  65. Watford WT, Hissong BD, Durant LR, Yamane H, Muul LM, Kanno Y, Tato CM, Ramos HL, Berger AE, Mielke L, Pesu M, Solomon B, Frucht DM, Paul WE, Sher A, Jankovic D, Tsichlis PN, O’Shea JJ. Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii. J Exp Med. 2008;205:2803–12.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2016

Authors and Affiliations

  • Dimitra Virla
    • 1
  • Christos Tsatsanis
    • 3
  • Aristides G. Eliopoulos
    • 1
    • 2
  1. 1.Molecular & Cellular Biology Laboratory, Division of Basic SciencesUniversity of Crete Medical SchoolHeraklionGreece
  2. 2.Institute for Molecular Biology & Biotechnology, Foundation of Research & Technology Hellas (FORTH)HeraklionGreece
  3. 3.Department of Clinical ChemistryUniversity of Crete Medical SchoolHeraklionGreece